Impact of prospero homeobox-1 on tumor cell behavior and prognosis in colorectal cancer

American Journal of Cancer Research

Volumn 5, Issue 11, 2015, Pages 3286-3300

  Park, Young Lan ^a   Myung, Eun ^a   Park, Sun Young ^a   Kim, Nuri ^a   Oak, Chan Young ^a   Myung, Dae Seong ^a   Cho, Sung Bum ^a   Lee, Wan Sik ^a   Kweon, Sun Seog ^a   Kim, Hyun Soo ^a   Joo, Young Eun ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Angiogenesis; Colorectal neoplasm; Prognosis; Proliferation; Prospero homeobox 1

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; HOMEODOMAIN PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROSPERO HOMEOBOX 1 PROTEIN; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MOLECULAR PATHOLOGY; ONCOGENE; PROSPERO HOMEOBOX 1 GENE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

EID: 85006192539     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Brenner H, Kloor M and Pox CP. Colorectal cancer. Lancet 2014; 383: 1490-502.
2. Park SH, Song CW, Kim YB, Kim YS, Chun HR, Lee JH, Seol WJ, Yoon HS, Lee MK, Lee JH, Bhang CS, Park JH, Park JY, Do BH, Park YD, Yoon SJ, Park CW, Yoon SM, Choi JH, Shin KC, Ko DH, Kim YJ, Seol DC. Clinicopathological characteristics of colon cancer diagnosed at primary health care institutions. Intest Res 2014; 12: 131-8.
3. Lee CK. Clinicopathological characteristics of newly diagnosed colorectal cancers in community gastroenterology practice. Intest Res 2014; 12: 87-9.
4. Chambers AF, Groom AC and MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-72.
5. Brabek J, Mierke CT, Rösel D, Veselỳ P, Fabry B. The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal 2010; 8: 22.
6. Kim ER and Kim YH. Clinical application of genetics in management of colorectal cancer. Intest Res 2014; 12: 184-93.
7. Mittal K, Ebos J and Rini B. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin Oncol 2014; 41: 235-51.
8. Gomes FG, Nedel F, Alves AM, Nör JE, Tarquinio SB. Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci 2013; 92: 101-7.
9. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 2014; 14: 159-72.
10. Steinestel K, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med 2014; 3: 17.
11. Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci 2014; 35: 479-88.
12. Guarino M, Rubino B and Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007; 39: 305-18.
13. Elsir T, Smits A, Lindström MS, Nistér M. Transcription factor PROX1: its role in development and cancer. Cancer Metastasis Rev 2012; 31: 793-805.
14. Shimoda M, Takahashi M, Yoshimoto T, Kono T, Ikai I, Kubo H. A homeobox protein, prox1, is involved in the differentiation, proliferation, and prognosis in hepatocellular carcinoma. Clin Cancer Res 2006; 12: 6005-11.
15. Akagami M, Kawada K, Kubo H, Kawada M, Takahashi M, Kaganoi J, Kato S, Itami A, Shimada Y, Watanabe G, Sakai Y. Transcriptional factor Prox1 plays an essential role in the antiproliferative action of interferon-gamma in esophageal cancer cells. Ann Surg Oncol 2011; 18: 3868-77.
16. Schneider M, Büchler P, Giese N, Giese T, Wilting J, Büchler MW, Friess H. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. Int J Oncol 2006; 28: 883-90.
17. Rodrigues MF, de Oliveira Rodini C, de Aquino Xavier FC, Paiva KB, Severino P, Moyses RA, López RM, DeCicco R, Rocha LA, Carvalho MB, Tajara EH, Nunes FD. PROX1 Gene is Differentially Expressed in Oral Cancer and Reduces Cellular Proliferation. Medicine 2014; 93: e192.
18. Nagai H, Li Y, Hatano S, Toshihito O, Yuge M, Ito E, Utsumi M, Saito H, Kinoshita T. Mutations and aberrant DNA methylation of the PROX1 gene in hematologic malignancies. Genes Chromosomes Cancer 2003; 38: 13-21.
19. Versmold B, Felsberg J, Mikeska T, Ehrentraut D, Köhler J, Hampl JA, Röhn G, Niederacher D, Betz B, Hellmich M, Pietsch T, Schmutzler RK, Waha A. Epigenetic silencing of the candidate tumor suppressor gene PROX1 in sporadic breast cancer. Int J Cancer 2007; 121: 547-54.
20. Laerm A, Helmbold P, Goldberg M, Dammann R, Holzhausen HJ, Ballhausen WG. Prosperorelated homeobox 1 (PROX1) is frequently inactivated by genomic deletions and epigenetic silencing in carcinomas of the bilary system. J Hepatol 2007; 46: 89-97.
21. Skog M, Bono P, Lundin M, Lundin J, Louhimo J, Linder N, Petrova TV, Andersson LC, Joensuu H, Alitalo K, Haglund CH. Expression and prognostic value of transcription factor PROX1 in colorectal cancer. Br J Cancer 2011; 105: 1346-51.
22. Miettinen M and Wang ZF. Prox1 transcription factor as a marker for vascular tumors-evaluation of 314 vascular endothelial and 1086 nonvascular tumors. Am J Surg Pathol 2012; 36: 351-9.
23. Elsir T, Qu M, Berntsson SG, Orrego A, Olofsson T, Lindström MS, Nistér M, von Deimling A, Hartmann C, Ribom D, Smits A. PROX1 is a predictor of survival for gliomas WHO grade II. Br J Cancer 2011; 104: 1747-54.
24. Elsir T, Eriksson A, Orrego A, Lindström MS, Nistér M. Expression of PROX1 is a common feature of high-grade malignant astrocytic gliomas. J Neuropathol Exp Neurol 2010; 69: 129-38.
25. Lu MH, Huang CC, Pan MR, Chen HH, Hung WC. Prospero homeobox 1 promotes epithelialmesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9. Clin Cancer Res 2012; 18: 6416-25.
26. Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K. Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell 2008; 13: 407-19.
27. Ragusa S, Cheng J, Ivanov KI, Zangger N, Ceteci F, Bernier-Latmani J, Milatos S, Joseph JM, Tercier S, Bouzourene H, Bosman FT, Letovanec I, Marra G, Gonzalez M, Cammareri P, Sansom OJ, Delorenzi M, Petrova TV. PROX1 promotes metabolic adaptation and fuels outgrowth of Wnt(high) metastatic colon cancer cells. Cell Rep 2014; 8: 1957-73.
28. Wiener Z, Högström J, Hyvönen V, Band AM, Kallio P, Holopainen T, Dufva O, Haglund C, Kruuna O, Oliver G, Ben-Neriah Y, Alitalo K. Prox1 promotes expansion of the colorectal cancer stem cell population to fuel tumor growth and ischemia resistance. Cell Rep 2014; 8: 1943-56.
29. Greene FL. American Joint Committee on Cancer, and American Cancer Society. AJCC cancer staging manual. 6th edition. New York: Springer-Verlag; 2002. xiv, pp. 421.
30. Kudo-Saito C. Cancer-associated mesenchymal stem cells aggravate tumor progression. Front Cell Dev Biol 2015; 3: 23.
31. Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. Semin Oncol 2015; 42 Suppl 1: S3-17.
32. Fulawka L, Donizy P and Halon A. Cancer stem cells-the current status of an old concept: literature review and clinical approaches. Biol Res 2014; 47: 66.
33. Li L and Li W. Epithelial-mesenchymal transition in human cancer: comprehensive reprogramming of metabolism, epigenetics, and differentiation. Pharmacol Ther 2015; 150: 33-46.
34. Liu X and Fan D. The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links. Curr Pharm Des 2015; 21: 1279-91.
35. Puisieux A, Brabletz T and Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014; 16: 488-94.
36. Bauer TM, Patel MR and Infante JR. Targeting PI3 kinase in cancer. Pharmacol Ther 2015; 146: 53-60.
37. Luo J. Glycogen synthase kinase 3beta (GSK-3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009; 273: 194-200.
38. Haagenson KK and Wu GS. Mitogen activated protein kinase phosphatases and cancer. Cancer Biol Ther 2010; 9: 337-40.